Volume 17, Number 2—February 2011
Dispatch
Pandemic (H1N1) 2009, Abu Dhabi, United Arab Emirates, May 2009–March 2010
Gulfaraz Khan
, Jamal Al-Mutawa, and Muhammad Jawad Hashim
, Jamal Al-Mutawa, and Muhammad Jawad Hashim
Table 2
Characteristics of 26 patients who died of pandemic (H1N1) 2009 infection, Abu Dhabi, United Arab Emirates, May 1, 2009–March 23, 2010
| Characteristic | Value |
|---|---|
| Gender, no. (%) | |
| M | 15 (59.7) |
| F |
11 (42.3) |
| Nationality, no. (%) | |
| United Arab Emirates | 12 (46.2) |
| Expatriates |
14 (53.8) |
| Age, y | |
| Mean | 43.8 |
| Median | 47.0 |
| Range |
0.67–83.00 |
| Signs and symptoms, no. (%) | |
| Fever | 19 (73.1) |
| Cough | 14 (53.8) |
| Breathing difficulty | 14 (53.8) |
| Other,* with or without above symptoms |
17 (65.4) |
| Underlying conditions, no. (%) | |
| Pregnancy | 6 (54.5) |
| Diabetes | 9 (34.6) |
| Malignancy | 7 (26.9) |
| Cardio/cerebrovascular disease | 2 (7.7) |
| Hypertension | 5 (19.2) |
| Asthma | 2 (7.7) |
| Other | 4 (15.4) |
| Not recorded |
6 (23.1) |
| Duration of oseltamivir treatment, d† | |
| Mean | 8.3 |
| Median | 5.0 |
| Range |
2–28 |
| Time from laboratory confirmation of pandemic (H1N1) 2009 infection to start of oseltamivir treatment, d‡ | |
| Mean | −3.2 |
| Median | −2.0 |
| Range |
−16 to 2 |
| Duration from hospitalization to death, d | |
| Mean | 27.5 |
| Median | 21 |
| Range | 1–86 |
*Sore throat, lung infiltration, diarrhea, headache, chest pain, abdominal pain.
†Although all patients with pandemic (H1N1) 2009 were treated with oseltamivir, the exact duration of treatment was known for only 12.
‡The exact date of laboratory confirmation of pandemic (H1N1) 2009 and start of oseltamivir treatment was known for only 21 of the 26 patients.
Page created: July 13, 2011
Page updated: July 13, 2011
Page reviewed: July 13, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.